학술논문
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.
Document Type
Journal Article
Author
Trudel, Sabrina; Jullien, Maxime; Blin, Nicolas; Gastinne, Thomas; Mahé, Béatrice; Dubruille, Viviane; Bonnet, Antoine; Lok, Anne; Chevallier, Patrice; Peterlin, Pierre; Garnier, Alice; Guillaume, Thierry; Le Bourgeois, Amandine; Tessoulin, Benoît; Le Gouill, Steven; Moreau, Philippe; Touzeau, Cyrille
Source
Subject
*MULTIPLE myeloma
*DEXAMETHASONE
*PROTEASOME inhibitors
*RETROSPECTIVE studies
*PROGRESSION-free survival
*
*
*
*
Language
ISSN
0939-5555
Abstract
Pomalidomide dexamethasone is a standard of care for relapsed multiple myeloma (MM) patients who received at least two prior lines of therapy, including both lenalidomide and proteasome inhibitors (PI). We report here a real-life single-center series of 49 consecutive patients with relapsed and refractory MM treated with the triplet pomalidomide cyclophosphamide dexamethasone (PCD) combination. The median of prior lines of therapy was 3 and all patients were previously exposed to proteasome inhibitors and lenalidomide. The overall response rate was 76%, including 27% very good partial response or better. With a median follow-up of 16 months, the median progression-free survival (PFS) was 7.3 months and the median overall survival was not reached. Regarding safety, most frequent toxicity was hematologic, including 37% grade 3-4 cytopenias. Nine patients (18%) discontinued therapy due to adverse event. Our study confirms that PCD combination is feasible and results in favorable response rate and PFS in comparison with pomalidomide dexamethasone alone. [ABSTRACT FROM AUTHOR]